Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI
Initiation of iGlarLixi in people with uncontrolled T2D is effective and safe in clinical practice, across different baseline HbA1c and BMI categories.
Authors
- Cristian Guja (ORCID: https://orcid.org/0000-0002-8703-0522)
- Martin Haluzı́k (ORCID: https://orcid.org/0000-0002-0201-6888)
- Nick Freemantle (ORCID: https://orcid.org/0000-0001-5807-5740)
- Mathilde Tournay
- Mireille Bonnemaire
- Jochen Seufert (ORCID: https://orcid.org/0000-0001-5654-7310)
- János Tibor Kis (ORCID: https://orcid.org/0009-0003-0415-797X)
- Carine Vera
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Charles University (CZ)
- University Medical Center Freiburg (DE)
- Sanofi (France) (FR)
- MRC Clinical Trials Unit at UCL (GB)
- International Drug Development Institute (Belgium) (BE)
- Szent János Kórház (HU)
- Institute of Clinical and Experimental Medicine (CZ)
- University College London (GB)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1007/s13300-024-01644-0
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Sanofi